To save from Bloodbath Blood Plasma company GRFS BX @ 33.45
Here is the leading Blood Plasma Company in the world
Barcelona, March 17, 2014: Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), one of the world's leading manufacturers of plasma-derived medicines, has concluded the debt refinancing process it launched on February 24, 2014, extending the maturity and improving the funding conditions of all tranches. The average cost of its debt has fallen below 3.5%, decreasing by more than 200 basis points (bps).
If you are afraid of bloodbath then invest in Plasma.